Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KVA12123,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Kineta
Deal Size : Undisclosed
Deal Type : Agreement
Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression
Details : The agreement aims to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.
Brand Name : KVA12123
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 18, 2023
Lead Product(s) : KVA12123,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Kineta
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Mustang Bio
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with follicular lymphoma.
Brand Name : MB-106
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 15, 2023
Lead Product(s) : MB-106
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Mustang Bio
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?